30 March 2023 | News
Multi-year strategic research partnership between Radiopharm Theranostics and GenesisCare
Image credit: shutterstock
Radiopharm Theranostics, a clinical-stage radiotherapeutics company, and GenesisCare, a leading global provider of integrated cancer care and theranostics research, have announced a new two-year strategic research collaboration to develop novel radiopharmaceuticals for some complex, hard-to-treat cancers.
Through the partnership, Radiopharm Theranostics and GenesisCare will conduct Phase 1 clinical trials in Australia to study the safety and tolerability of novel radiopharmaceuticals, focusing on areas of high unmet need in oncology.
As part of the collaboration, GenesisCare’s Contract Research Organisation (CRO) and Imaging Research Organisation (IRO), have been engaged to implement three Phase 1 clinical trials in Australia, involving Radiopharm’s platform of radiopharmaceutical nanobodies.
Radiopharmaceuticals are designed to deliver small doses of radiation to specifically targeted cells for either therapeutic or diagnostic purposes. Effective cancer radiopharmaceuticals require tumour-specific targets not found in healthy tissue. To date, the majority of clinical developments in radiopharmaceuticals have targeted metastatic prostate cancer and neuroendocrine tumours.